US 12,215,387 B2
Biomarker predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment
Dominik Feuerbach, Basel (CH); Baltazar Gomez-Mancilla, Basel (CH); Yunsheng He, Cambridge, MA (US); Donald Johns, Cambridge, MA (US); Cristina Lopez-Lopez, Basel (CH); Kevin Hall McAllister, Basel (CH); Nicole Pezous, Basel (CH); Lisa Sandford, Basel (CH); and Markus Weiss, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Jun. 1, 2022, as Appl. No. 17/829,859.
Application 15/788,942 is a division of application No. 14/735,288, filed on Jun. 10, 2015, granted, now 9,828,642, issued on Nov. 28, 2017.
Application 17/829,859 is a continuation of application No. 15/788,942, filed on Oct. 20, 2017, granted, now 11,359,241.
Application 14/735,288 is a continuation of application No. PCT/IB2013/060744, filed on Dec. 9, 2013.
Claims priority of provisional application 61/735,720, filed on Dec. 11, 2012.
Prior Publication US 2022/0316011 A1, Oct. 6, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); A61K 9/20 (2006.01); A61K 31/439 (2006.01); A61K 31/444 (2006.01); A61K 45/06 (2006.01); C12Q 1/6883 (2018.01); A61K 9/16 (2006.01); A61K 9/48 (2006.01)
CPC C12Q 1/6883 (2013.01) [A61K 9/2018 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/2086 (2013.01); A61K 31/439 (2013.01); A61K 31/444 (2013.01); A61K 45/06 (2013.01); A61K 9/1623 (2013.01); A61K 9/1652 (2013.01); A61K 9/4858 (2013.01); A61K 9/4866 (2013.01); A61K 2300/00 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/172 (2013.01)] 20 Claims
 
1. A method for treating an individual suffering from schizophrenia, the method comprising:
administering a therapeutically effective amount of an alpha 7 nicotinic acetylcholine receptor activator to the individual, wherein the individual is selected by:
determining that a genotype of the individual at the genetic locus of the human cytochrome P450, family 1, sub-family A, polypeptide 2 (CYP1A2) gene includes:
(i) a homozygous SNP genotype of rs2069514-A/A; or
(ii) a heterozygous SNP genotype of rs2069514-A/G; or
(iii) a SNP forming a haplotype with said SNP genotypes or a SNP in the same linkage disequilibrium with said SNP genotypes.